We are committed to developing a new generation of medicines: monoclonal microbial therapies.
We will use our breakthrough translational approach, our unique relationships with our partners and our passion to devise new ways to prevent and treat diseases.
We are scientists from the fields of medicine, drug development, molecular biology, and process engineering.
Co-founder, Chief Executive Officer
Dr. Philippe Langella
Co-founder, Preclinical Advisor
Prof. Harry Sokol
Co-founder, Clinical Advisor
Prof. Patrick Gervais
Co-founder, Manufacturing Advisor